Cargando…

JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes

Detalles Bibliográficos
Autores principales:	Sureau, Léa, Buors, Caroline, Ianotto, Jean-Christophe, Boyer, Françoise, Tanguy-Schmidt, Aline, Roy, Lydia, Cayssials, Emilie, Cailly, Laura, Chomel, Jean-Claude, Chauveau, Aurélie, Orvain, Corentin, Mansier, Olivier, Ranta, Dana, Robles, Margot, Gyan, Emmanuel, Hérault, Olivier, Nimubona, Stanislas, Marchand, Tony, Lippert, Eric, Riou, Jérémie, Ugo, Valérie, Luque Paz, Damien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993923/ https://www.ncbi.nlm.nih.gov/pubmed/35395836 http://dx.doi.org/10.1038/s41408-022-00646-0

Ejemplares similares

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
por: Le Calloch, Ronan, et al.
Publicado: (2018)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review
por: Ianotto, Jean-Christophe, et al.
Publicado: (2019)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis
por: Sureau, Léa, et al.
Publicado: (2021)

Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values
por: Silver, Richard T., et al.
Publicado: (2019)

Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera
por: Yikilmaz, Aysun Şentürk, et al.
Publicado: (2020)

Updates in the management of polycythemia vera and essential thrombocythemia
por: Bose, Prithviraj, et al.
Publicado: (2019)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Novel therapeutic strategies for essential thrombocythemia/polycythemia vera
por: Yoon, Seug Yun, et al.
Publicado: (2023)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: Conchon, Monika
Publicado: (2011)

An agenda for future research projects in polycythemia vera and essential thrombocythemia
por: Barbui, Tiziano, et al.
Publicado: (2020)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
por: Li, Xiao-qing, et al.
Publicado: (2022)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
por: Pósfai, Éva, et al.
Publicado: (2016)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival
por: Accurso, Vincenzo, et al.
Publicado: (2020)

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2016)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
por: Lussana, Federico, et al.
Publicado: (2017)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
por: Sacco, Monica, et al.
Publicado: (2020)

Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study
por: Accurso, Vincenzo, et al.
Publicado: (2019)

Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression
por: Song, Jihyun, et al.
Publicado: (2022)

The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease’s phenotype
por: Sobieralski, Patryk, et al.
Publicado: (2023)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

The Association Between Gene Polymorphisms and Leukocytosis with Thrombotic Complications in Patients with Essential Thrombocythemia and Polycythemia Vera
por: Mehtap, Özgür, et al.
Publicado: (2012)

Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis
por: Murata, Makoto, et al.
Publicado: (2020)

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
por: Sun, Yingxin, et al.
Publicado: (2021)

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
por: Podoltsev, Nikolai A., et al.
Publicado: (2023)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gq0u7ajouf3mse9eglh9gj95p3